| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.1 |